Obeticholic Acid

奥贝胆酸

Report date: 2026/05/14 20:00:28
NMEFirst In Class

Base Information

Drug NameObeticholic Acid
Drug Alias Name6α-ethyl chenodeoxycholic acid6α-乙基鹅去氧胆酸acidum obeticholicum6-ethyl-chenodeoxycholic-acidZektayos-Hepjuvo +[10] 
ClassificationSmall molecules > Steroids
Mechanisms of ActionBile acid receptor FXR agonists
TargetsBile acid receptor FXR
Therapy Area/IndicationsEsophageal adenocarcinomaFibrosisObesity +[16] 
Global Approved IndicationsCholangitis, Sclerosing
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2016/05/27
Country/TerritoryBelgiumCanadaUnited States +[31] 
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaNDA/BLA
Originator CompaniesIntercept Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesKing Edward Medical UniversityNational Cancer InstituteThe University Of Texas MD Anderson Cancer Center +[6] 
Inactive CompaniesAarhus UniversityMedical University Of ViennaNational Institute Of Diabetes And Digestive And Kidney Diseases +[4] 
Active IndicationsEsophageal adenocarcinomaFibrosisMetabolic Dysfunction-Associated Steatotic Liver Disease +[8] 
Inactive IndicationsObesityDiabetes Mellitus, Type 2Hepatitis, Alcoholic +[8] 

Other Information

ATC CodeA05AA04
Related LinksWikipediaDrugBankKEGG